Global DDI Solutions’ Post

Highly recommended this webinar relevant for any one involved in the treatment of patients with lung cancer. Learn everything about drug-drug interactions, the pros and cons of TDM, and management of toxicity, including discussion of ESMO - European Society for Medical Oncology guidelines. You are all welcome!!

Insightful article shared by Clarivate for Life Sciences & Healthcare Oncology team published in Nature Drug Discovery!! Our authors mention in the article "Between 2023 and 2032, the market will become increasingly crowded, with novel drugs expected to gain approval." Click below to read more. #Clarivateoncology #oncology #targetedtherapy #HER2positive #triplenegative

Dr Rik Van Severen of University Hospitals Leuven reveals promising outcomes from a study on alpelisib combined with antihormonal therapy for hormone receptor-positive, HER2-negative metastatic breast cancer. With a clinical benefit rate of 26.3% and manageable side effects, this research marks a significant step forward for PIK3CA-mutated breast cancer treatment. Despite some discontinuations due to toxicity, the findings affirm alpelisib’s role as a next-generation therapy with a noteworthy safety profile. Discover these vital insights. 👇 For all SABCS 2023 videos, find the link in the comments! #SABCS2023 #BreastCancerResearch #Alpelisib #OncologyInnovation

#capecitabine #capetero500mgCapetero 500mg Tablet (Capecitabine) is an oral chemotherapy medication used for treating various cancers, including breast and colorectal cancer. It is metabolized into 5-fluorouracil (5-FU) in the body, effectively inhibiting the growth of cancer cells.

Cancer is the leading indication for co-drug therapies, with more than 3,000 co-therapy cancer programs currently underway. PharmaCircle’s exclusive Co-Therapy Short Report presents the powerful and significant results of two drugs coming together to combat cancer and the potential for more targeted treatments. Learn more in The Weekly Brief https://lnkd.in/eCbZrP9. #Cancer #CoTherapy #SmallMolecule #PrecisionMedicine

🌟 𝗡𝗲𝘄 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: “𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗚𝗜 𝗖𝗮𝗻𝗰𝗲𝗿” 🌟 Prof Marc Van den Eynde & Prof Eric Van Cutsem unveil new standards in HER2-Positive Gastric Cancer Treatment. This episode delves into the KEYNOTE-811 study's significant findings, demonstrating the enhanced efficacy and safety of combining pembrolizumab with trastuzumab and chemotherapy for HER2-positive gastric cancer patients. The study marks a milestone in cancer treatment, offering a beacon of hope for patients and setting new benchmarks for future therapies. 👇 Watch the full video  link in the comments! #MediMix #HER2Positive #GastricCancer #OncologyInnovation

Approximately 36% of patients diagnosed with lung cancer receive the correct treatment. The AMCP Market Insights Best Practice webinar brings together Daryl Pritchard, Precision Medicine Coalition, and Susan Wescott, Mayo Clinic to discuss the key findings of the market insights roundtable on gaps that exist in the precision medicine side of non-small cell lung cancer (NSLC). View the NSLC Best Practice webcast today: https://bit.ly/4efCk4W #oncology #lungcancer #managedcare #pharmacy

New results are in! The phase 3 CROWN study compared lorlatinib, a brain-penetrant, third-generation ALK tyrosine kinase inhibitor, with crizotinib in treatment-naive patients with advanced ALK+ non-small cell lung cancer (NSCLC). After 5 years of follow-up, lorlatinib demonstrated remarkable efficacy and safety outcomes. Lorlatinib’s sustained efficacy and IC benefits underscore its potential as a first-line therapy for ALK+ NSCLC. Clinicians should consider these findings when tailoring treatment strategies. Exciting progress! Watch OncLive's video to learn more about the study from Massachusetts General Hospital's Dr. Ibiayi Dagogo-Jack. #LungCancer #PrecisionOncology #MedicalResearch https://lnkd.in/gWGWE-YV

To overcome resistance to antihormonal and HER2-targeted agents mediated by cyclin D1-CDK4/6 complex, we proposed an oral combination of the HER2 inhibitor tucatinib, aromatase inhibitor letrozole, and CDK4/6 inhibitor palbociclib (TLP combination) for treatment of HR./HER2. metastatic breast cancer (MBC). Learn about Criterium's cutting-edge breast cancer research. https://lnkd.in/e_GemRaz #BreastCancerAwareness

🤔 Can we predict patients' response to chemotherapy? 🤷♀️ And how useful is it? Well, we did some research! 🕵️♀️ ➡️ As a result of a basket trial we performed using data from >200 patients from three indications (bladder, lung and ovarian cancer), we can now generate patient reports like this one, showing which chemotherapy type the ovarian cancer cells in this patient are most sensitive to! 👇 We will continue to collaborate with both patients and doctors, to further evaluate the value and application of our testing to support treatment decisions. Download the full poster showcasing our results here! 📍 https://lnkd.in/eriz7YMx  #personalizedmedicine #exvivotumortesting #ESMO24